SG11201708604TA - Oncolytic adenovirus encoding a b7 protein - Google Patents

Oncolytic adenovirus encoding a b7 protein

Info

Publication number
SG11201708604TA
SG11201708604TA SG11201708604TA SG11201708604TA SG11201708604TA SG 11201708604T A SG11201708604T A SG 11201708604TA SG 11201708604T A SG11201708604T A SG 11201708604TA SG 11201708604T A SG11201708604T A SG 11201708604TA SG 11201708604T A SG11201708604T A SG 11201708604TA
Authority
SG
Singapore
Prior art keywords
protein
oncolytic adenovirus
adenovirus encoding
encoding
oncolytic
Prior art date
Application number
SG11201708604TA
Other languages
English (en)
Inventor
Brian Robert Champion
Alice Claire Noel Bromley
Original Assignee
Psioxus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1507419.8A external-priority patent/GB201507419D0/en
Priority claimed from GBGB1516936.0A external-priority patent/GB201516936D0/en
Priority claimed from GBGB1522013.0A external-priority patent/GB201522013D0/en
Application filed by Psioxus Therapeutics Ltd filed Critical Psioxus Therapeutics Ltd
Publication of SG11201708604TA publication Critical patent/SG11201708604TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201708604TA 2015-04-30 2016-04-29 Oncolytic adenovirus encoding a b7 protein SG11201708604TA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1507419.8A GB201507419D0 (en) 2015-04-30 2015-04-30 Virus
GBGB1516936.0A GB201516936D0 (en) 2015-09-24 2015-09-24 Virus
GBGB1522013.0A GB201522013D0 (en) 2015-12-14 2015-12-14 Virus
PCT/EP2016/059609 WO2016174200A1 (en) 2015-04-30 2016-04-29 Oncolytic adenovirus encoding a b7 protein

Publications (1)

Publication Number Publication Date
SG11201708604TA true SG11201708604TA (en) 2017-11-29

Family

ID=56008588

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201803081TA SG10201803081TA (en) 2015-04-30 2016-04-29 Oncolytic adenovirus encoding a b7 protein
SG11201708604TA SG11201708604TA (en) 2015-04-30 2016-04-29 Oncolytic adenovirus encoding a b7 protein
SG10201901482XA SG10201901482XA (en) 2015-04-30 2016-04-29 Oncolytic adenovirus encoding a b7 protein

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201803081TA SG10201803081TA (en) 2015-04-30 2016-04-29 Oncolytic adenovirus encoding a b7 protein

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201901482XA SG10201901482XA (en) 2015-04-30 2016-04-29 Oncolytic adenovirus encoding a b7 protein

Country Status (31)

Country Link
US (6) US11000559B2 (enExample)
EP (2) EP3288573B1 (enExample)
JP (3) JP6931229B2 (enExample)
KR (4) KR102854512B1 (enExample)
CN (2) CN107690479B (enExample)
AU (3) AU2016256582B2 (enExample)
BR (2) BR112017023171A2 (enExample)
CA (1) CA2984038C (enExample)
CL (2) CL2017002731A1 (enExample)
CO (1) CO2017010831A2 (enExample)
CY (1) CY1122833T1 (enExample)
DK (1) DK3288573T3 (enExample)
EA (1) EA037611B1 (enExample)
ES (1) ES2780366T3 (enExample)
HR (1) HRP20200439T1 (enExample)
HU (1) HUE048320T2 (enExample)
IL (3) IL284375B (enExample)
LT (1) LT3288573T (enExample)
MX (1) MX2017013684A (enExample)
MY (1) MY183703A (enExample)
PE (2) PE20181140A1 (enExample)
PH (1) PH12017501942A1 (enExample)
PL (1) PL3288573T3 (enExample)
PT (1) PT3288573T (enExample)
RS (1) RS60105B1 (enExample)
SA (2) SA517390260B1 (enExample)
SG (3) SG10201803081TA (enExample)
SI (1) SI3288573T1 (enExample)
SM (1) SMT202000222T1 (enExample)
WO (1) WO2016174200A1 (enExample)
ZA (1) ZA201801589B (enExample)

Families Citing this family (38)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015030881A2 (pt) 2013-06-14 2017-10-24 Psioxus Theraupeutics Ltd Ā“regime de dosagem e formulaƧƵes para adenovĆ­rus de tipo bĀ”
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
LT3021859T (lt) 2013-10-25 2018-06-11 Psioxus Therapeutics Limited Onkolitiniai adenovirusai su heterologiniais genais
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
HRP20200439T1 (hr) 2015-04-30 2020-06-12 Psioxus Therapeutics Limited Onkolitički adenovirus koji kodira protein b7
BR112018008865A8 (pt) 2015-11-02 2019-02-26 Five Prime Therapeutics Inc polipeptĆ­deos do domĆ­nio extracelular cd80 e seu uso no tratamento do cĆ¢ncer
MY193281A (en) * 2015-12-17 2022-09-30 Psioxus Therapeutics Ltd Group b adenovirus encoding an anti-tcr-complex antibody or fragment
SI3436591T1 (sl) * 2016-03-31 2023-05-31 The European Molecular Biology Laboratory Dostavni vehikli, izpeljani iz proteina adenovirusne ovojnice
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
KR102427563B1 (ko) 2016-08-29 2022-08-03 ģ‹øģ“ģ˜¤ģ„œģŠ¤ ķ…Œė¼ķ“Øķ‹±ģŠ¤ ģ—˜ķ‹°ė””. ģ“ģ¤‘ķŠ¹ģ“ģ„± T ģ„øķ¬ ķ™œģ„±ķ™”ģ œ(Bispecific T cell activator)ź°€ ė³“ź°•ėœ ģ•„ė°ė…øė°”ģ“ėŸ¬ģŠ¤
EP4282969A3 (en) 2016-09-02 2024-01-31 Lentigen Technology, Inc. Compositions and methods for treating cancer with duocars
CN117085047A (zh) * 2016-09-27 2023-11-21 čØē‰¹ę²»ē–—å­¦ęœ‰é™å…¬åø 优化ēš„ęŗ¶ē˜¤ē—…ęƒ及其ē”Ø途
WO2018083258A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083257A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083259A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
EP3577132A4 (en) * 2017-02-03 2021-03-10 University of Pittsburgh - of The Commonwealth System of Higher Education ONCOLYTIC VIRUS THERAPY
MX2019012849A (es) 2017-04-28 2019-11-28 Five Prime Therapeutics Inc Metodos de tratamiento con polipeptidos del dominio extracelular del cd80.
BR112019024656A2 (pt) * 2017-05-25 2020-06-09 Univ Central Florida Res Found Inc vĆ­rus oncolĆ­ticos para a sensibilizaĆ§Ć£o de cĆ©lulas tumorais para morte por cĆ©lulas exterminadoras naturais
NZ759833A (en) * 2017-05-26 2023-01-27 Epicentrx Inc Recombinant adenoviruses carrying transgenes
CN118308311A (zh) * 2017-06-01 2024-07-09 é˜æ協ē±³ę–Æē”Ÿē‰©å…¬åø ęŗ¶ē˜¤ē—…ęÆ’å’Œę–¹ę³•
WO2019147921A1 (en) 2018-01-26 2019-08-01 Nantcell, Inc. Rapid verification of virus particle production for a personalized vaccine
GB201801614D0 (en) * 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
WO2019173334A1 (en) * 2018-03-05 2019-09-12 The Schepens Eye Research Institute, Inc. Engineered vegf variants for retinal neuroprotection, promotion of axon growth and axon regeneration
KR20200136972A (ko) * 2018-03-30 2020-12-08 ė„ėŖØķ‚¤ ė„ė„ ģ¢…ģ°½ ė°œģƒ ģ–µģ œķ˜• ģ¢…ģ–‘ ģš©ķ•“ģ„± ė°”ģ“ėŸ¬ģŠ¤
JP2022502074A (ja) * 2018-09-10 2022-01-11 ć‚øć‚§ćƒć‚»ć‚¤ćƒ« 惐悤ć‚Ŗ惆惃ć‚Æļ¼ˆć‚·ćƒ£ćƒ³ćƒć‚¤ļ¼‰ć‚«ćƒ³ćƒ‘ćƒ‹ćƒ¼ ćƒŖ惟惆惃惉 ę”¹å¤‰ć•ć‚ŒćŸč…«ē˜ęŗ¶č§£ę€§ć‚¦ć‚¤ćƒ«ć‚¹ć€ēµ„ęˆē‰©ć€ćŠć‚ˆć³ćć®ä½æē”Ø
CN113439123A (zh) * 2019-03-05 2021-09-24 安čæ›å…¬åø ęŗ¶ē˜¤ē—…ęƒē”ØäŗŽę²»ē–—ē™Œē—‡ēš„ē”Ø途
EP3725323A1 (en) * 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
EP3970754A4 (en) * 2019-05-14 2023-08-02 Oncolys BioPharma, Inc. METHOD OF ADMINISTRATION OF ONCOLYTIC VIRUS TO TUMOR TISSUE AND DEVICE FOR ADMINISTRATION
GB201909081D0 (en) 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
MX2022015872A (es) 2020-06-11 2023-05-16 Provention Bio Inc Metodos y composiciones para prevenir diabetes tipo 1.
GB202102049D0 (en) * 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses
EP4332218A4 (en) * 2021-06-03 2024-09-18 Shanghai Yunying Biopharmaceutical Technology Co., Ltd. ONCOLYTIC VIRUS VECTOR AND USE THEREOF
US20240398939A1 (en) 2021-09-23 2024-12-05 Sagittarius Bio, Inc. Adenoviruses and methods for using adenoviruses
EP4499846A1 (en) * 2022-03-25 2025-02-05 UniversitƤt ZĆ¼rich Adenoviral mediated targeting of activated immune cells
WO2024243578A1 (en) 2023-05-25 2024-11-28 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses

Family Cites Families (75)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thƩrapie gƩnique.
FI951138L (fi) 1993-07-13 1995-04-13 Rhone Poulenc Rorer Sa Puuttellisia adenovirusvektoreita ja niiden kƤyttƶ geeniterapiassa
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
US5877011A (en) 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
CN1242051A (zh) 1996-12-31 2000-01-19 ę˜‚å°¼å…‹ę–ÆčÆē‰©å…¬åø ē”ØäŗŽč‚æē˜¤ę²»ē–—和预防ēš„臓ē»†čƒžē—…变ē—…ęƒ
US6420524B1 (en) 1997-02-20 2002-07-16 Johns Hopkins University School Of Medicine Gain of function mutations in ATP-dependent transposition proteins
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US20020019051A1 (en) 1998-05-27 2002-02-14 Monika Lusky Chimeric adenoviral vectors
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
CN1110553C (zh) 1998-07-15 2003-06-04 ę­å·žčµ›ē‹®ē”Ÿē‰©ęŠ€ęœÆå¼€å‘ęœ‰é™å…¬åø åŸŗå› å·„ē؋č…ŗē—…ęƒ及其ē”Ø途
AU767975B2 (en) 1998-09-11 2003-11-27 Genvec, Inc. Alternatively targeted adenovirus
CA2678259C (en) 1998-12-09 2016-10-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services A recombinant vector expressing multiple costimulatory molecules and uses thereof
DK1681353T3 (da) 1999-05-17 2010-01-04 Crucell Holland Bv Af adenovirus afledte genoverfƶrselsvehikler indeholdende mindste Ʃt element af adenovirus type 35
WO2000073478A2 (en) 1999-06-01 2000-12-07 University Of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
US7396679B2 (en) 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
US7223593B2 (en) * 2000-01-21 2007-05-29 Biovex Limited Herpes virus strains for gene therapy
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
JP2003534806A (ja) 2000-05-31 2003-11-25 ć‚øć‚§ćƒ³ćƒ™ć‚Æć€ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ć‚£ćƒƒćƒ‰ ć‚¢ćƒ‡ćƒŽć‚¦ć‚¤ćƒ«ć‚¹ćƒ™ć‚Æć‚æćƒ¼ć®ć‚æćƒ¼ć‚²ćƒ†ć‚£ćƒ³ć‚°ć®ę–¹ę³•ćŠć‚ˆć³ēµ„ęˆē‰©
ATE449859T1 (de) 2001-01-04 2009-12-15 Goeran Wadell Virusvektor zur gentherapie
US20050175589A1 (en) 2001-07-13 2005-08-11 Btg International Limited Anti-neoplastic viral agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
CA2474777A1 (en) 2002-02-01 2003-08-07 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with pods
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
WO2003092594A2 (en) 2002-04-30 2003-11-13 Duke University Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
CN1705740B (zh) * 2002-10-15 2013-07-24 佩尔Ā·ę¾å†…Ā·éœå°”姆 å…·ęœ‰åå‘åŸŗ因č”Øč¾¾ēš„č…ŗē—…ęƒ及其åŗ”ē”Ø
US20040167088A1 (en) 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo
US20040213764A1 (en) 2003-03-28 2004-10-28 William Wold Adenovirus replication-competent vectors expressing trail
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
CN1934253A (zh) 2003-07-18 2007-03-21 ę˜‚å°¼å…‹ę–ÆčÆē‰©å…¬åø ē”ØäŗŽę²»ē–—ē–¾ē—…ēš„bäŗšē»„č…ŗē—…ęÆ’č½½ä½“
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
WO2005107474A2 (en) 2004-04-30 2005-11-17 Introgen Therapeutics, Inc. Oncolytic adenovirus armed with therapeutic genes
CA2567094C (en) 2004-05-26 2014-11-25 Schering Aktiengesellschaft Chimeric adenoviruses for use in cancer treatment
CN100361710C (zh) 2004-06-07 2008-01-16 ęˆéƒ½åŗ·å¼˜ē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø č‚æē˜¤ē»†čƒžäø“äø€č”Øč¾¾å…ē–«č°ƒčŠ‚因子gm-csfēš„ęŗ¶ē˜¤ę€§č…ŗē—…ęƒ重ē»„体ēš„ęž„å»ŗ及其åŗ”ē”Ø
US20060292682A1 (en) * 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
CN101068933A (zh) * 2004-08-25 2007-11-07 ē»†čƒžåŸŗ因ē³»ē»Ÿęœ‰é™å…¬åø ē”ØäŗŽč‚æē˜¤ē»†čƒžå¢žå¼ŗč½¬åƼēš„ēŗ¤ē»“äæ®é„°ēš„č…ŗē—…ęÆ’č½½ä½“
CA2589602A1 (en) * 2004-09-01 2006-04-13 Genvec, Inc. Adenoviral vectors able to transduce apcs, potential use in immune response generation
EP1819823A2 (en) 2004-12-01 2007-08-22 Bayer Schering Pharma Aktiengesellschaft Generation of replication competent viruses for therapeutic use
CA2620495A1 (en) 2005-08-31 2007-03-08 Genvec, Inc. Adenoviral vector-based malaria vaccines
DE102005055128B4 (de) 2005-11-15 2015-04-02 UniversitƤt Rostock Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
ES2304281B1 (es) 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
US8216819B2 (en) 2006-12-22 2012-07-10 Psioxus Therapeutics Limited Generation of oncolytic adenoviruses and uses thereof
CA2723580A1 (en) 2008-05-27 2009-12-03 Oncolytics Biotech Inc. Modulating interstitial pressure and oncolytic viral delivery and distribution
CN101381742A (zh) * 2008-10-23 2009-03-11 ęµ™ę±Ÿē†å·„大学 ꙚꜟåÆåŠØå­é¶å‘ę€§č°ƒęŽ§ęŗ¶ē˜¤č…ŗē—…ęƒpCN305č½½ä½“åŠå…¶ęž„å»ŗę–¹ę³•äøŽåŗ”ē”Ø
ES2385251B1 (es) * 2009-05-06 2013-05-06 FundaciĆ³ Privada Institut D'investigaciĆ³ BiomĆØdica De Bellvitge Adenovirus oncolĆ­ticos para el tratamiento del cĆ”ncer.
WO2011043719A1 (en) * 2009-10-05 2011-04-14 Ya-Fang Mei Replicating viral vectors for gene therapy
KR101957616B1 (ko) 2010-08-16 2019-03-12 ė” ģ†”ķ¬ ģøģŠ¤ķ‹°ķŠœķŠø ķ¬ ė°”ģ“ģ˜¬ė”œģ§€ģ¹¼ ģŠ¤ķ„°ė””ģ¦ˆ ģ•„ė°ė…øė°”ģ“ėŸ¬ģŠ¤ ģ”°ė¦½ ė°©ė²•
CN103221423B (zh) * 2010-09-24 2015-09-30 ę˜‚å…‹ę–Æę²»ē–—ęœ‰é™å…¬åø ęŗ¶ē˜¤č…ŗē—…ęÆ’č½½ä½“åŠäøŽå…¶ē›ø关ēš„ę–¹ę³•å’Œē”Ø途
WO2012038606A1 (en) 2010-09-24 2012-03-29 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies
WO2013074507A2 (en) 2011-11-14 2013-05-23 Regenerative Sciences, Llc Suspended particle delivery systems and methods
CN102586327B (zh) 2012-01-18 2013-09-11 陕č„æåøˆčŒƒå¤§å­¦ äø€ę­„ę³•ęž„å»ŗęŗåø¦å¤–ęŗåŸŗ因ēš„d24ēŗ¤ē»“蛋ē™½äæ®é„°ēš„ę”件复制型č…ŗē—…ęÆ’č½½ä½“åŠå…¶åŗ”ē”Ø
WO2014138314A1 (en) 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
LT3021859T (lt) 2013-10-25 2018-06-11 Psioxus Therapeutics Limited Onkolitiniai adenovirusai su heterologiniais genais
CN106029889A (zh) 2013-11-22 2016-10-12 德那ēæ äøęœ‰é™å…¬åø č”Øč¾¾å…ē–«ē»†čƒžåˆŗęæ€å—体ęæ€åŠØ剂ēš„č…ŗē—…ęƒ
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
GB201510197D0 (en) * 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
GB201503500D0 (en) 2015-03-02 2015-04-15 Ucl Business Plc Cell
KR102626276B1 (ko) 2015-03-17 2024-01-17 ķ‹øķŠø ė°”ģ“ģ˜¤ģ„øėŸ¬ķ“Øķ‹±ģŠ¤ ģ˜¤ģ“ ģ“-ķŠ¹ģ“ģ ģø ķ•­ģ²“ė„¼ ģ•”ķ˜øķ™”ķ•˜ėŠ” ģ¢…ģ–‘ė¶•ź““ģ„± ģ•„ė°ė…øė°”ģ“ėŸ¬ģŠ¤ ė° ģ“ģ™€ ź“€ė Øėœ ė°©ė²• ė° ģš©ė„
HRP20200439T1 (hr) 2015-04-30 2020-06-12 Psioxus Therapeutics Limited Onkolitički adenovirus koji kodira protein b7
MY193281A (en) 2015-12-17 2022-09-30 Psioxus Therapeutics Ltd Group b adenovirus encoding an anti-tcr-complex antibody or fragment
KR20180118198A (ko) 2016-03-18 2018-10-30 ė‚œķŠøģ…€, ģøķ¬. ģˆ˜ģ§€ģƒ ģ„øķ¬ ź°ģ—¼ģ„ ģœ„ķ•œ ė©€ķ‹°ėŖØė‹¬ ė²”ķ„°(multimodal vector for dendritic cell infection)
KR102427563B1 (ko) 2016-08-29 2022-08-03 ģ‹øģ“ģ˜¤ģ„œģŠ¤ ķ…Œė¼ķ“Øķ‹±ģŠ¤ ģ—˜ķ‹°ė””. ģ“ģ¤‘ķŠ¹ģ“ģ„± T ģ„øķ¬ ķ™œģ„±ķ™”ģ œ(Bispecific T cell activator)ź°€ ė³“ź°•ėœ ģ•„ė°ė…øė°”ģ“ėŸ¬ģŠ¤
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
AU2017345764A1 (en) 2016-10-20 2019-05-02 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083259A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
CN118308311A (zh) * 2017-06-01 2024-07-09 é˜æ協ē±³ę–Æē”Ÿē‰©å…¬åø ęŗ¶ē˜¤ē—…ęÆ’å’Œę–¹ę³•
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation

Also Published As

Publication number Publication date
IL258044A (en) 2018-05-31
US10322152B2 (en) 2019-06-18
US20170266243A1 (en) 2017-09-21
CN108396015A (zh) 2018-08-14
ZA201801589B (en) 2019-10-30
US10124028B2 (en) 2018-11-13
AU2016256582A1 (en) 2017-11-16
CA2984038C (en) 2023-01-03
MX2017013684A (es) 2018-08-28
SG10201803081TA (en) 2018-06-28
HRP20200439T1 (hr) 2020-06-12
AU2018201446B2 (en) 2020-05-28
US20170056458A1 (en) 2017-03-02
JP2021176339A (ja) 2021-11-11
KR20250134212A (ko) 2025-09-09
US10849945B2 (en) 2020-12-01
SA517390260B1 (ar) 2021-11-10
PE20181140A1 (es) 2018-07-17
WO2016174200A1 (en) 2016-11-03
CN107690479B (zh) 2022-02-18
CO2017010831A2 (es) 2018-02-28
EP3288573A1 (en) 2018-03-07
JP6928380B2 (ja) 2021-09-01
EP3391892A1 (en) 2018-10-24
IL255286A0 (en) 2017-12-31
BR112017023171A2 (pt) 2018-07-17
IL284375A (en) 2021-07-29
KR20240032177A (ko) 2024-03-08
SA520412637B1 (ar) 2022-03-01
HUE048320T2 (hu) 2020-07-28
CY1122833T1 (el) 2021-05-05
IL258044B (en) 2021-07-29
US20180140649A1 (en) 2018-05-24
EA037611B1 (ru) 2021-04-21
IL284375B (en) 2022-07-01
US20210338753A1 (en) 2021-11-04
JP6931229B2 (ja) 2021-09-01
CN108396015B (zh) 2022-02-18
AU2016256582B2 (en) 2020-10-29
PT3288573T (pt) 2020-03-25
JP2018514199A (ja) 2018-06-07
CL2017002731A1 (es) 2018-06-08
LT3288573T (lt) 2020-03-25
SG10201901482XA (en) 2019-03-28
CL2018000587A1 (es) 2018-08-10
US10548929B2 (en) 2020-02-04
JP7162929B2 (ja) 2022-10-31
PH12017501942A1 (en) 2018-03-19
CA2984038A1 (en) 2016-11-03
DK3288573T3 (da) 2020-03-16
AU2018201446A1 (en) 2018-03-29
ES2780366T3 (es) 2020-08-25
US11000559B2 (en) 2021-05-11
KR102643574B1 (ko) 2024-03-06
PL3288573T3 (pl) 2020-05-18
AU2016256582A8 (en) 2018-01-18
EP3288573B1 (en) 2020-02-12
PE20180241A1 (es) 2018-01-31
KR20180022638A (ko) 2018-03-06
JP2018139586A (ja) 2018-09-13
KR102854512B1 (ko) 2025-09-04
BR122018004815A2 (pt) 2019-09-10
HK1249009A1 (en) 2018-10-26
AU2020223665A1 (en) 2020-09-10
IL255286B (en) 2021-01-31
SI3288573T1 (sl) 2020-06-30
RS60105B1 (sr) 2020-05-29
US20190076493A1 (en) 2019-03-14
CN107690479A (zh) 2018-02-13
MY183703A (en) 2021-03-09
KR20180118249A (ko) 2018-10-30
EA201791971A1 (ru) 2018-04-30
SMT202000222T1 (it) 2020-05-08
US20180042973A1 (en) 2018-02-15

Similar Documents

Publication Publication Date Title
IL258044A (en) Oncolytic adenovirus encoding the b7 protein
IL260027A (en) A group b adenovirus that encodes an anti-tcr-complex antibody or particle
ZA201802261B (en) Polypeptides
PL3659614T3 (pl) Onkolityczny wirus krowianki
IL254577A0 (en) polypeptides
GB201713765D0 (en) Modified adenovirus
GB201409634D0 (en) Intra block copy mode encoding choice
PL3303293T3 (pl) Modulatory ROR-gamma
PL3303290T3 (pl) Modulatory ROR-gamma
PL3303291T3 (pl) Modulatory ROR-gamma
ZA201704366B (en) Il-17a-binding polypeptides
SG11201706882VA (en) Polypeptides
PL3319942T3 (pl) MODULATORY ROR-GAMMA (RORĪ³)
GB201417535D0 (en) Adapting encoding properties
IL267267A (en) Vibration sensing system with wavelength encoding
EP3239962A4 (en) Encoding device
GB2539417B (en) Optimized multi-view image encoding
GB201520655D0 (en) Multi-mode sensor
GB201614607D0 (en) Modified adenovirus
GB201706219D0 (en) Modified adenovirus
GB201700663D0 (en) Modified adenovirus
GB201401159D0 (en) Adenovirus
GB201516655D0 (en) IX sensor
GB201502178D0 (en) Detecting polypeptides
GB201403024D0 (en) Polypeptides